Mr. FADZ JABAR United States

Venn Biosciences innovates cancer diagnostics using Artificial Intelligence (AI) and next-gen mass spectrometry, unlocking glycoproteomics for Biomarker and Target Discovery.
Website:
intervenn.com
Company Size (Fulltime employees)
Year of foundation
2017
Please specify your partnering goal
partnership and clients
Headquartner in China
Your Research Tool and Service name
venn vista
Service Description
tool for biomarker discovery and diagnostic
INTERVENN BIOSCIENCES
VICE PRESIDENT, BUSINESS DEVELOPMENT 
Functionality

Dr. Chirag Jain India

Life science-focused Innovation licensing organizations looking to commercialize global innovations for the Indian and South Asian markets through a unique partnership-led model.
GCV Life
Analyst 
Functionality

Olivier Jarry United States

Libera Bio develops a new family of cancer treatments based on its patented actively targeted delivery technology to intracellular targets (MPN – Multifunctional Polymeric Nanocapsules) and on novel monoclonal antibodies (e.g. anti KRAS), with the goal to have them commercialized by large biopharma companies after regulatory approval for clinical trials or early proof-of-concept in humans.

Libera Bio lead candidate aims at providing a new treatment for those highly prevalent and aggressive cancers which are driven by KRAS mutations, such as pancreatic cancer, lung cancer and colorectal cancer.
Year of foundation
2018
Headquartner in China
Biotech/Pharma Asset Stage
Libera Bio
MS, MBA 
Functionality

PENG Jason China

跨国Medtech集团
Website:
www.bbraun.com
Partnering Objectives
Headquartner in China
贝朗医疗
BD副总监 

Fan Jason China

Mend Biotech’s full name is Mend Biotechnology Incorporation, and its English name is Mend Biotech Inc. ( MBT). It is a multinational research institution focusing on the field of regenerative medicine to treat various skeletal-related diseases. The founding team consists of Professors and Scientists in Cedars-Sinai Medical center, UCLA and Harvard University and the kick school of medicine in USC, and the CEO of a multinational biotechnology company. In June 2020, MBT settled in CHENGDU TianFu international Bio-town as a key project introduced by Chengdu High-tech zone government. MBT received 13.5 million Chinese yuan in seed round investment by Mr. chen keming, chairman of keming noodle industry, a listed company in China. A follow on angel round is expected to generate an investment of 40 million. GMP and cGMP lab are currently under construction in both China and US.
Partnering Objectives
Headquartner in China
Mend Biotech
R&D Scientist 

Tan Jenen United States

Allakos is a public-traded clinical-stage biopharmaceutical company developing first-in-class antibody-based therapeutics to treat allergic and inflammatory diseases.
Website:
www.allakos.com
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
Tan Jenen
Allakos
LinkedIn logo Sr Manager, Market Planning 

Mr. Jacob Jeong United States

Bio ingredients supplier
Website:
Www.kerry.com
Company Size (Fulltime employees)
Year of foundation
1976
Partnering Objectives
Please specify your partnering goal
Market insight
Headquartner in China
Kerry
BD Director 
Functionality

Xiangjiao Jia China

细胞与基因治疗
Website:
www.pregene.com
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
深圳普瑞金生物药业有限公司
BD经理 

chunchao jia China

medical device company focUnited States on blood purification
Website:
www.cmtdl.com.cn
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
kangyuan biomedical tech
department leader 

Joy Jian United States

Health analytics
Website:
ArborMetrix.com
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
Get to know China market
Headquartner in China
Biotech/Pharma Category
ArborMetrix
Quality Manager